BioSpace News Archive

Strategikon Pharma announced today the release of Clinical Maestro® SOURCE version 3.0.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today presented additional confirmatory data from its Gaucher disease program.

MicroTransponder®, Inc. reached a milestone Tuesday with the first commercial use of its Vivistim® Paired VNS™ System.

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today presented updates to its two lead programs at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference.

Xcelerate, Inc. recently announced that it had signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a company engaged in oncology research and the development of human and animal health care and medical products, as well as cosmetics and beauty products.

VESTECK, Inc. is pleased to announce their participation and strong podium presence at the Charring Cross International Vascular Symposium.

With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs.

QIAGEN N.V. announced that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference held in Denver, Colorado.

Satsuma Pharmaceuticals, Inc. announced that John Kollins, its President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference and invites investors to participate via webcast or in-person in Miami, FL on May 24 -25, 2022.